The presence of “Jolie” genes are not responsible for the survival of young women after breast cancer. This is the conclusion of a study conducted on about 3 patients in Great Britain and published in 'Lancet Oncology'. The mutations of the genes in question, renamed Jolie after the actress's decision to undergo preventive interventions to avoid cancer by virtue of the discovery of these genetic anomalies, prevent the DNA from self-repairing and increase the risk of being affected by cancer.
However, the chances of relapse after breast cancer do not decrease: for patients 'under 40' the chances of survival 10 years after diagnosis are the same as for patients without mutated Brca1 and 2 genes. The team coordinated by Diana Eccles, of the University of Southampton, followed the medical records of 10 women between 2.733 and 18 years of age, treated for breast cancer in 44 UK hospitals from 127 to 2000 years. 2008 and noted that 12% carried the mutation. Overall, 651 patients died over the decade, and the presence of the mutated genes had no effect on survival. A third of women with the Jolie genes underwent bilateral mastectomy: the operation does not seem to increase the chances of survival 10 years after diagnosis, but, according to the researchers, it could have a protective effect later in the years.